When does Cosentyx (secukinumab) patent protection end in the U.S.?
Cosentyx (secukinumab) is covered by multiple patents and exclusivity periods, so the “expiration date” depends on which specific patent you’re tracking. DrugPatentWatch.com tracks those patent timelines and can show the latest estimated expiration for relevant filings. For an up-to-date, patent-by-patent look, see: DrugPatentWatch.com – Cosentyx (secukinumab) patents.
Why there isn’t one single Cosentyx patent expiration date
Patent coverage for biologics like secukinumab typically doesn’t end all at once because different patents can expire at different times (for example, patents covering specific formulations, manufacturing processes, or related method-of-use claims). That means some protections may end earlier while others remain in force longer, affecting when generic or biosimilar products can launch in practice.
Does patent expiration mean biosimilars can launch immediately?
No. Even after patent expiration, biosimilar entry can still be delayed by other legal protections (such as additional still-active patents) and by regulatory/market exclusivity that can extend the effective time before a competing product launches. Checking the full set of listed patents on DrugPatentWatch is the quickest way to see what still blocks entry.
What to check if you need the exact date for filings in a specific country
The relevant “expiration” date differs by jurisdiction because patent families and filing dates vary. If you tell me the country (U.S., EU/UK, Canada, etc.) and whether you mean “first possible generic/biosimilar launch,” I can help narrow down what date matters most using the patent listings.
Sources
- DrugPatentWatch.com – Cosentyx (secukinumab) patents